The Immune Response Corporation

Research Corporation Technologies, Inc.

Ronald B Luftig

Jorge Velarde

Danuta Pieniazek

Norman J Pieniazek

Susan B Slemenda

This invention is directed toward mutated DNA, proteins, or protein fragments and particles from the L-2 cell line. The invention is also directed to diagnostic, prophylactic and therapeutic methods of making and using the DNA, proteins and particles.

Non-infectious, protease defective HIV particles and nucleic acid molecules encoding therefor

The present invention relates to DNA and proteins of human adenovirus Type 41 and their use in detection of said virus. More specifically, the present invention relates to the isolation of a 41.4 kd short fiber protein and a 60.6 kd long fiber protein of adenovirus type 41 (Ad41), as well as proteins derived from the Ad41 E3 region, thereby providing virus-derived antigens and active derivatives and parts thereof, useful in the development of diagnostic assays, DNA probes and vaccines for said virus or other related viruses belonging to the human enteric adenovirus family. In addition, the present invention is directed to recombinant DNA molecules containing the human enteric adenovirus Type 41 Tak long fiber protein gene, the Ad41 short fiber protein gene and the Ad41 E3 gene (encoding the Ad41 proteins RL-1 to RL-6) thereby providing a source of recombinant viral components useful in the development of said diagnostic assays, DNA probes and vaccines for human adenoviruses. The present invention is also directed to first antibodies specific to the above-identified Ad41 viral components and to second antibodies specific to the first antibodies. These second antibodies are also useful in the development of diagnostic assays for Ad41 and other adenoviruses.

Growing community of inventors

Metairie, LA, United States of America

Ronald B Luftig